At 92Bio, we are leveraging the latest advances in multi-specific antibody design and novel immune cell subsets to create fit-for-purpose T-cell engagers (TCEs).  Our potentially best-in-class FRα x CD3 TCE, NTB-928, is on track to enter the clinic in the first half of 2026. We are also on the cutting edge of γδ T-cell activating therapy development; our first γδ T-cell-engaging drug, for the treatment of acute myeloid leukemia, is slated to enter the clinic in 2027. Exciting future projects in solid and hematologic tumors are not far behind.  

How we work is as important as why we work at 92Bio. We’re a tight-knit, collaborative team that encourages clear-eyed engagement with risk, a growth mindset, and diversity of thought. Innovation thrives here through trust, inclusion, and a shared purpose. Part of that purpose is a sense of community—we’re proud to support local philanthropic efforts alongside our efforts to help patients worldwide.
As we grow, we remain committed to scientific excellence, collaboration, and relentless focus on patient impact.

Learn more about our science and team at 92biotech.com.

92Bio, Inc.

Org chart

Teams

Offices